Supplementary Figures – Cost-Effectiveness of Immune checkpoint inhibitors for non-small cell lung cancer as a second line in Taiwan

Supplementary Figure 1. Cost-Effectiveness of Immune checkpoint inhibitors for non-small cell lung cancer as a second line in Taiwan

Model structure and transitions

Supplementary Figure 2: Cost-Effectiveness of Immune checkpoint inhibitors for non-small cell lung cancer as a second line in Taiwan

Kaplan-Meier and fitted (Log logistic distribution) overall survival and progression-free survival curves for non-small cell lung cancer, Docetaxel.

Supplementary Figure 3: Cost-Effectiveness of Immune checkpoint inhibitors for non-small cell lung cancer as a second line in Taiwan

Kaplan-Meier and fitted (Log-normal distribution)overall survival and progression-free survival curves for non-small cell lung cancer, Nivolumab

Supplementary Figure 4: Cost-Effectiveness of Immune checkpoint inhibitors for non-small cell lung cancer as a second line in Taiwan

Kaplan-Meier and fitted (Log logistic distribution) overall survival and progression-free survival curves for non-small cell lung cancer, Pembrolizumab.

Supplementary Figure 5: Cost-Effectiveness of Immune checkpoint inhibitors for non-small cell lung cancer as a second line in Taiwan

Kaplan-Meier and fitted (Log logistic distribution) overall survival and progression-free survival curves for non-small cell lung cancer, Atezolizumab.